Salute e Benessere
Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented at EBJIS 2025
The Biocomposites symposium, titled , will be moderated by Dr Massimiliano De Paolis and Professor Pierluigi Viale , and will feature leading clinicians discussing innovations in infection management for complex and high-risk patient groups.
The session will include Dr Matteo Monami, lead author of the BIG D-FOOT study, presenting results from the first double-blind, randomised controlled trial evaluating local antibiotic delivery using STIMULAN in diabetic foot osteomyelitis (DFO).
Key findings from the BIG D-FOOT study include:
These results provide strong clinical and economic validation for the use of STIMULAN in managing complex diabetic foot infections, offering surgeons an effective, localised strategy for improving outcomes in challenging DFO cases.
"We are delighted to support the annual meeting of the European Bone & Joint Infection Society (EBJIS) again this year, and to highlight the growing body of evidence supporting STIMULAN 's use in managing serious infections. The BIG D-FOOT study represents an important milestone in demonstrating the clinical and economic benefits of using STIMULAN for local antibiotic delivery when treating diabetic foot osteomyelitis."
Details of Biocomposites' symposium at the EBJIS Annual Meeting are listed below.
: From diabetic foot osteomyelitis to peri-prosthetic joint infection: what are the most appropriate treatment strategies?
: Room Sala Italia, Bologna Congress Centre
: Friday 12 September 2025 , 12:50-13:50 CEST
:
:
Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe , South America , USA , Canada , China and India . Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites products are now used in over 1 million procedures per annum and sold in more than 100 countries around the world. Please visit biocomposites.com to learn more.
The European Bone & Joint Infection Society (EBJIS) is a dedicated community of medical professionals and scientists committed to advancing knowledge and fostering excellence in the prevention and treatment of musculoskeletal infections. Its annual meeting is a premier event bringing together experts, practitioners, and industry leaders for high-level scientific exchange and networking. For more information, visit https://ebjis.org/ebjis2025/
View original content:https://www.prnewswire.co.uk/news-releases/results-from-big-d-foot-study-using-stimulan-when-treating-dfo-to-be-presented-at-ebjis-2025-302549606.html